Fina Biosolutions, LLC mission is to help manufacture affordable conjugate vaccines for emerging markets. We are a global provider of conjugate vaccine laboratory and consulting services for the Biotech and Vaccine industry, with core expertise in conjugation chemistry, bioconjugation and conjugate vaccines.

Fina Biosolutions’ Molecular Biology Group has developed an E. coli strain for producing carrier proteins.

• CRM₁₉₇ and rTTHc are available for preclinical use
• CRM₁₉₇ is available for clinical use (GMP)

Fina Biosolutions has applied its expertise in polysaccharide conjugation to the production and characterization of functionalized dextrans and related products.  Our products include:

• amino and carboxy dextrans
• fluorescent dextrans
• unique mono and multi-functionalized dextrans.